Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cRGDY-PEG-Cy5.5-C dots for Nodal Metastases Mapping in Head and Neck Cancer
NCT02106598Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2014
- Primary completion
- Apr 2027
- Modality
- Polymer-based Nanoparticles, Peptides, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cRGDY-PEG-Cy5.5-C dots in head and neck cancer (HNC), melanoma, squamous cell carcinoma (SCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2014; status: active, not recruiting.
02
Drugs
cRGDY-PEG-Cy5.5-C dots
03
Conditions
head and neck cancer (HNC)melanomasquamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02106598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106598.